Your browser doesn't support javascript.
loading
Interferon-associated therapies toward HIV control: The back and forth.
Noël, Nicolas; Jacquelin, Béatrice; Huot, Nicolas; Goujard, Cécile; Lambotte, Olivier; Müller-Trutwin, Michaela.
Afiliação
  • Noël N; Institut Pasteur, Unité HIV, Inflammation & Persistence, Paris, France; Assistance Publique - Hopitaux de Paris, Service de Médecine Interne et Immunologie Clinique, Hopitaux Universitaires Paris Sud, Le Kremlin-Bicêtre, France; INSERM/CEA U1184, Immunologie des Maladies Virales et Autoimmunes,
  • Jacquelin B; Institut Pasteur, Unité HIV, Inflammation & Persistence, Paris, France.
  • Huot N; Institut Pasteur, Unité HIV, Inflammation & Persistence, Paris, France.
  • Goujard C; Assistance Publique - Hopitaux de Paris, Service de Médecine Interne et Immunologie Clinique, Hopitaux Universitaires Paris Sud, Le Kremlin-Bicêtre, France; Faculté de Médecine Paris Sud, Le Kremlin-Bicêtre, France; CESP, INSERM U1018, Le Kremlin Bicêtre, France.
  • Lambotte O; Assistance Publique - Hopitaux de Paris, Service de Médecine Interne et Immunologie Clinique, Hopitaux Universitaires Paris Sud, Le Kremlin-Bicêtre, France; INSERM/CEA U1184, Immunologie des Maladies Virales et Autoimmunes, Le Kremlin Bicêtre, France; Faculté de Médecine Paris Sud, Le Kremlin-Bicêtr
  • Müller-Trutwin M; Institut Pasteur, Unité HIV, Inflammation & Persistence, Paris, France. Electronic address: mmuller@pasteur.fr.
Cytokine Growth Factor Rev ; 40: 99-112, 2018 04.
Article em En | MEDLINE | ID: mdl-29555233
ABSTRACT
Human immunodeficiency virus (HIV) induces a persistent and incurable infection. However, the combined antiretroviral treatment (cART) has markedly changed the evolution of the infection and transformed a deadly disease into a manageable chronic infection. Withdrawal of cART generally leads though to resumption of the viral replication. The eradication of the virus from its cellular and anatomical reservoirs remains a goal-to-achieve for a cure. In this context, developing novel therapies contributing to this aim are an important field of research. Type I IFN has antiviral activity, which, before the presence of efficient anti-HIV drugs, has led to the testing of IFN-based therapeutic strategies during the early years of the pandemic. A historical overview of the results and its limitations that were put into light are reviewed here. In addition, several lessons could be drawn. For instance, the efficacy of the IFN-I depends on the timing of its administration and the context. Thus, the persistence of an endogenous IFN-signature, such as that generally observed in viremic patients, seems to be associated with a lower efficacy of IFN. Based on the lessons from previous trials, and in the context of cART and research for a cure, type I Interferon has regained interest and novel therapeutic approaches are currently tested in combination with cART, some with disappointing, other with encouraging results with regard to a reduction in the size of the HIV reservoir and/or delays in viral rebound after cessation of cART. Additional strategies are currently developed in addition to improve the antiviral function of the IFN-I, by using for instance other IFN subtypes than IFN-Iα2. In parallel, the development of innovative strategies aimed at counteracting the excessive activation of the IFN-pathways have been continued and their results are reviewed here as well. Altogether, the use of IFN-I in anti-HIV therapies has gone through distinct phases and many lessons could be drawn. Novel combinations are currently be tested that might provide interesting results.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Problema de saúde: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles Assunto principal: Infecções por HIV / HIV-1 / Interferon-alfa / Fármacos Anti-HIV Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Cytokine Growth Factor Rev Assunto da revista: ALERGIA E IMUNOLOGIA / BIOQUIMICA Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Problema de saúde: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles Assunto principal: Infecções por HIV / HIV-1 / Interferon-alfa / Fármacos Anti-HIV Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Cytokine Growth Factor Rev Assunto da revista: ALERGIA E IMUNOLOGIA / BIOQUIMICA Ano de publicação: 2018 Tipo de documento: Article
...